Nakamura, K.* ; Saredi, G.* ; Becker, J.R.* ; Foster, B. ; Nguyen, N.V.* ; Beyer, T.E.* ; Cesa, L.C.* ; Faull, P.A.* ; Lukauskas, S. ; Frimurer, T.* ; Chapman, J.R.* ; Bartke, T. ; Groth, A.*
H4K20meO recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids.
Nat. Cell Biol. 21, 311-318 (2019)
Genotoxic DNA double-strand breaks (DSBs) can be repaired by error-free homologous recombination (HR) or mutagenic non-homologous end-joining(1). HR supresses tumorigenesis(1), but is restricted to the S and G2 phases of the cell cycle when a sister chromatid is present(2). Breast cancer type 1 susceptibility protein (BRCA1) promotes HR by antagonizing the anti-resection factor TP53-binding protein 1(53BP1) (refs. (2-5)), but it remains unknown how BRCA1 function is limited to the S and G2 phases. We show that BRCA1 recruitment requires recognition of histone H4 unmethylated at lysine 20 (H4K2OmeO), linking DSB repair pathway choice directly to sister chromatid availability. We identify the ankyrin repeat domain of BRCA1-associated RING domain protein 1 (BARD1)-the obligate BRCA1 binding partner(3)-as a reader of H4K2OmeO present on new histones in post-replicative chromatin(6). BARD1 ankyrin repeat domain mutations disabling H4K2OmeO recognition abrogate accumulation of BRCA1 at DSBs, causing aberrant build-up of 53BP1, and allowing anti-resection activity to prevail in S and G2. Consequently, BARD1 recognition of H4K2OmeO is required for HR and resistance to poly (ADP-ribose) polymerase inhibitors. Collectively, this reveals that BRCA1-BARD1 monitors the replicative state of the genome to oppose 53BP1 function, routing only DSBs within sister chromatids to HR.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Post-replicative Chromatin; Dna-damage; Structural Basis; Repair; 53bp1; Brca1; Suppression; Stability; Resection; Complex
Keywords plus
Language
Publication Year
2019
Prepublished in Year
HGF-reported in Year
2019
ISSN (print) / ISBN
1465-7392
e-ISSN
1476-4679
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 21,
Issue: 3,
Pages: 311-318
Article Number: ,
Supplement: ,
Series
Publisher
Nature Publishing Group
Publishing Place
Macmillan Building, 4 Crinan St, London N1 9xw, England
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502800-001
Grants
Copyright
Erfassungsdatum
2019-03-15